Ahmedabad-based Cadila Healthcare received an approval from the US Food & Drug Administration to market multiple doses of Risperidone tablets, which is prescribed for the treatment of schizophrenia.

The company has received approval for 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg doses of Risperidone. The group has now 41 approvals and has so far filed 79 Abbreviated New Drug Application (ANDAs) since 2003-04.